Crescita Therapeutics Reports Fourth Quarter and Fiscal 2018 Results Record Annual Revenue of $16.6M and Adjusted EBITDA of $1.5M Strong Royalties and Sales Milestones

Stock Information for Crescita Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Crescita Therapeutics Inc.

Crescita Therapeutics Announces the Results of its Annual General and Special Meeting of Shareholders
Crescita Therapeutics Announces Mutual Termination of Licensing Agreement with Croma Pharma GmbH for Pliaglis®
Crescita Reports First Quarter 2025 Results
Crescita Reports Q4 and Fiscal 2024 Results
Crescita Reports Third Quarter 2024 Results
Crescita Therapeutics Announces Approval of Normal Course Issuer Bid
Crescita to Present & Participate in 1x1 Meetings at the Planet MicroCap Showcase: VANCOUVER 2024 in Association with Small Cap Discoveries on Thursday, September 26, 2024
Crescita Reports Second Quarter 2024 Results

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.